Ann: September 2021 Quarterly Activities Report and Appendix 4C, page-9

  1. 1,301 Posts.
    lightbulb Created with Sketch. 6
    We seem to be adding patents at a rapid rate, Veyonda's pharmacology is starting to take shape as both an anti-inflammatory/cytokine storm blocker and it's blocking of Sphingosine-1-phosphate in cancer cells which augments the activity of checkpoint inhibitors, radiation and chemotherapy.
    We are currently stuck with the worst patients and providing great results. To me IONIC is the most exciting but as always with biotechs we are on the cusp of the next big thing, I think we will be partnering within 6 months based on Lupin results and our ongoing patent protection. I have topped up on Noxo in anticipation.

    GLTAH
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.0¢
Change
0.001(2.04%)
Mkt cap ! $14.61M
Open High Low Value Volume
5.0¢ 5.1¢ 5.0¢ $14.75K 295K

Buyers (Bids)

No. Vol. Price($)
1 763 5.0¢
 

Sellers (Offers)

Price($) Vol. No.
5.1¢ 49807 1
View Market Depth
Last trade - 16.10pm 04/07/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.